Welcome to our dedicated page for STEMTECH CORPORATION news (Ticker: STEK), a resource for investors and traders seeking the latest updates and insights on STEMTECH CORPORATION stock.
Stemtech Corporation (OTCQB:STEK) generates news around its activities in stem cell nutrition, wellness, anti‑aging, and pet health. The company describes itself as a global leader and pioneer in stemceuticals™ – all‑natural, plant‑based nutraceutical products designed to support the body’s own regenerative processes. News updates often highlight how Stemtech advances its stem cell nutrition platform, expands distribution, and develops new product lines for both humans and pets.
Investors and observers following STEK news can expect coverage of product launches and enhancements, such as the RCM System (stemrelease3™, StemFlo® Advanced, MigraStem®), OraStem® Toothpaste, Cellect One® Shield: HOCL, Cellect One® Rapid Renew Stem Cell Peptide Night Cream, and the StemPets™ pet supplement line for dogs and cats. Company announcements also describe educational initiatives like the “Well‑Aging” video series hosted by Dr. Lizette Leos, MD, which discusses cellular regeneration, biohacking, and stem cell nutrition.
Stemtech’s news flow also includes international growth developments. Recent releases describe joint ventures for Stemtech HealthSciences India Pvt Ltd in partnership with Innoventure Dynamic LLP, plans for Stemtech Asia (Hong Kong) with Lightway Ventures to distribute products in China, and an exclusive licensing agreement with Energy International Development Co., Ltd. for Taiwan. Operational updates, such as resolving backorders of core stem cell nutrition products and manufacturing and distribution arrangements, are also part of the company’s communications.
Leadership and scientific updates feature prominently, including appointments such as the Chief Scientific Officer role for Dr. Lizette Leos and collaborations with clinicians like Dr. Sabine Hazan, MD, to design clinical trials on the RCM System. For readers tracking STEK, this news page offers a centralized view of Stemtech’s product, scientific, and international expansion announcements.
Stemtech Corporation (OTCQB: STEK) announced the appointment of Margie and Mike Mares to its Field Advisory Board. The Mares, who quickly progressed to Diamond Director within six months of joining in July 2021, bring extensive experience in network marketing. Stemtech aims for enhanced transparency and collaboration between its corporate and field teams. The company, recognized for its stemceutical products, continues to innovate and expand its offerings, including the recent launch of the CellectOne™ Rapid Renew Stem Cell Peptide Night Cream.
Stemtech Corporation (OTCQB: STEK) announced that its Taiwan branch received recognition from a government agency monitoring multi-level marketing (MLM) businesses. During a summit on December 19, General Manager Richard Hu highlighted the rarity of long-term success in Taiwan's MLM sector, with Stemtech being operational for 14 years, placing it in the top 10% of MLM companies. CEO Charles Arnold praised the team's contributions, while plans for a Business Academy in Taiwan were discussed to foster growth in 2023. New products are set to launch early next year, aiming to further propel business expansion.
Stemtech Corporation (OTCQB: STEK) announced that its Research and Development division, Life Factor Research, has secured its first contract to produce a white label product for a new client. The client is set to introduce an OTC Flu and Cold product in Q1 2023, utilizing a registered Pharmacopeia formulation with proven efficacy against airborne viruses. The partnership is expected to leverage both the client's ecommerce expertise and LFR's distribution channels, aiming for strong market penetration.
Stemtech Corporation (OTCQB: STEK) announced the success of its Leadership Event held at the Dreams Playa Mujeres Resort in Cancun, Mexico. The event celebrated Independent Business Partners (IBPs) from multiple countries, showcasing new products and sharing personal success stories. CEO Charles Arnold highlighted the positive impact of the event, emphasizing the passion and entrepreneurial successes of IBPs. Moving forward, the company plans to establish business academies in 2023, focusing on training and recognition. Stemtech specializes in natural, plant-based stemceuticals aimed at boosting health and wellness.
Stemtech Corporation (OTCQB:STEK) launched its new CellectOne skincare line, debuting with the Rapid Renew Stem Cell Peptide Night Cream. This product was developed by Stemtech's Life Factor Research division, focusing on innovative stem cell nutrition. CEO Charles S. Arnold highlighted the company’s commitment to health and wellness through cutting-edge science. The introduction of CellectOne marks a strategic advancement, with plans for additional products to enhance the skincare market. The company aims to drive growth through its direct sales model and expand its international network.
Stemtech Corporation (OTCQB: STEK) has promoted Alejandro Carrillo to Vice President of Global Sales from his previous role as Managing Director of Latin Markets. Under his leadership, Stemtech's Latin markets grew by over 40% this year. Carrillo expressed excitement about directing the company's commercial strategy and highlighted the company’s commitment to developing stemceutical products. CEO Charles S. Arnold endorsed Carrillo's promotion and mentioned an impressive sales program in development.
Stemtech Corporation (OTCQB: STEK) announced the participation of Board Director Darryl V. Green at the RHK Capital Disruptive Growth Conference in New York City on December 5, 2022. He will present the company's growth potential while CEO Charles S. Arnold and President John W. Meyer attend a leadership event in Cancun. Green, with over 30 years in health and nutrition, previously drove GNC's market cap from $1B to $3.7B. He believes Stemtech is positioned for significant growth in stemceutical and skincare products, driven by innovative technology.
Stemtech Corporation (OTCQB:STEK) announced enhancements to its AdvanceOffice mobile app, designed to improve efficiency for Independent Business Partners (IBPs). Launched in September 2022, the app provides vital tools for IBPs to promote Stemtech's products. Upcoming features include business analytics reports and CRM integration to streamline performance tracking. The company aims to drive growth through technological innovation in its direct sales model, continuing its legacy of pioneering stem cell nutrition.
Stemtech Corporation (OTCQB:STEK) announced significant advancements in the stem cell nutrition sector, emphasizing the rising investment in R&D, projected to reach $4.5 billion by 2027. President John W. Meyer highlighted the launch of new stemceuticals focusing on health and wellness, with a skincare product debuting at the December Cancun event. Tully & Holland noted a growing consumer focus on health post-pandemic, while CEO Cliff Layton projected revolutionary products from their R&D division, Life Factor Research. Founded in 2018, Stemtech continues to innovate in the stem cell market.
Stemtech Corporation (OTCQB: STEK) has finalized an acquisition agreement with Life Factor Research, enhancing its capabilities in research, development, and product formulation in the nutraceutical sector. This strategic move is expected to enable Stemtech to introduce innovative health products targeting anti-aging and longevity. Both companies express optimism about the vast potential this partnership brings, particularly given Life Factor Research's proprietary technologies and formulations.